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ABSTRACT 
 
Modelling of clinical-effectiveness in cost-effectiveness analysis typically involves 
some form of partitioned survival or Markov decision-analytic modelling. The health 
states progression-free, progression and death and the transitions between them are 
frequently of interest. With partitioned survival, progression is not modelled directly 
as a state; instead time in that state is derived from the difference in area between 
overall survival and progression-free survival curves. With Markov decision-analytic 
modelling, a priori assumptions are often made with regard to the transitions rather 
than using the individual patient data directly to model them. This article compares a 
multi-state modelling survival regression approach to these two common methods. 
As a case study, we use a trial comparing rituximab in combination with fludarabine 
and cyclophosphamide versus fludarabine and cyclophosphamide alone for the first 
line treatment of chronic lymphocytic leukaemia. We calculated mean Life Years and 
QALYs that involved extrapolation of survival outcomes in a trial. We adapted an 
existing multi-state modelling approach to incorporate parametric distributions for 
transition hazards, to allow extrapolation. The comparison showed that, due to the 
different assumptions used in the different approaches, a discrepancy in results was 
evident. The partitioned survival and Markov decision-analytic modelling deemed the 
treatment cost-effective with ICERs of just over £16,000 and £13,000 respectively. 
However, the results with the multi-state modelling were less conclusive with an 
ICER of just over £29,000. This work has illustrated that it is imperative to check 
whether assumptions are realistic as different model choices can influence clinical 
and cost-effectiveness results.  
 
INTRODUCTION 
Partitioned survival [1-3] and Markov decision-analytic modelling [4-7] are two 
methods widely used in cost-effectiveness analysis. In oncology, the three health 
states progression-free, progression and death are frequently of interest. Partitioned 
survival only considers the two curves progression-free survival and overall survival 
directly, with time in progression calculated using the difference in area between the 
two other curves. In contrast, Markov decision-analytic modelling studies the clinical 
pathway of disease by considering the three states progression-free, progression 
and death and the relevant transitions between them. All three relevant transitions 
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are considered simultaneously rather than the separate modelling of the two 
outcomes in partitioned survival. Markov decision-analytic models are typically built 
in a spreadsheet-based package over discrete time cycles using cohort simulation, 
and a priori assumptions are made with regards to the transition probabilities. Such 
assumptions are based on what the modeller deems appropriate, and therefore may 
not be based directly on the observed data for every transition. For example, 
background mortality rates are sometimes used to inform transition probabilities. In 
this article we use the alternative approach of multi-state modelling for comparison 
with partitioned survival and Markov decision-analytic modelling. Like Markov 
decision-analytic modelling, multi-state modelling is a state-transition modelling 
approach and as such models each of the transitions of interest simultaneously. 
However it uses a continuous-time framework. Typically, the individual patient level 
data is used to build survival regression models for each of the transitions and 
therefore the modelling is based wholly on the observed data. There has been 
increased awareness of multi-state modelling in the health economics literature [8-
10], however the method is still not commonly applied. In [8], the authors describe 
the use of tunnel states in Markov decision-analytic modelling as a way of building 
semi-Markov models that relax the Markov property. They implement a semi-Markov 
approach that represents tunnel states in an alternative way by using multi-
dimensional transition matrices. In [9], the authors use a multi-state model to inform 
a microsimulation model for cost-effectiveness analysis. It used exact times of 
transitions and as such negated discrete cycles and provided an alternative to tunnel 
states, thereby simplifying the process in situations with many health states. The 
mstate [11] package in R [12] was used for their multi-state modelling and Excel for 
their microsimulation model. In this paper we build on previous work to calculate 
transition probabilities. We adapt the existing functionality of mstate based on semi-
parametric Cox regression to incorporate parametric regression of transition 
hazards, with a range of standard distributions, to allow for extrapolation of survival 
outcomes and hazards that vary over time. Our illustration of the multi-state 
modelling approach involves this extrapolation and calculates mean Life Years 
/QALYs in relevant health states for use in cost-effectiveness analysis. Our approach 
focuses entirely on multi-state modelling and therefore provides an alternative to 
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microsimulation. Its implementation in R is described in [10], allowing other modellers 
to adopt the approach.  
Extrapolation of survival has received much attention in the health economics 
literature in recent years [13-18]. Extrapolation of survival is often needed because 
observation in clinical trials is frequently not of sufficient length to follow each patient 
to end of life. One way of extrapolating survival is to use parametric regression. 
Latimer [13] and Bagust [14] have debated approaches to estimating survival from 
Kaplan-Meier curves for outcomes used in partitioned survival, such as overall 
survival and progression-free survival. The multi-state modelling approach presented 
in this article extends this to state-transition modelling. The contribution of this paper 
is to compare this multi-state modelling approach to the two other common methods 
of partitioned survival and Markov decision-analytic modelling, with a particular 
emphasis on the different assumptions used with each of the approaches.  
 
DATA AND METHODS 
Dataset used for illustration 
 
 To compare the multi-state modelling framework with the two common 
approaches of partitioned survival and Markov decision-analytic modelling, a specific 
National Institute for Health and Clinical Excellence (NICE) technology appraisal is 
used for illustration - TA174 [19]. The economic model submitted by the 
manufacturer Roche to evaluate the cost-effectiveness of rituximab for first line 
treatment of chronic lymphocytic leukaemia is used as an example [20]. Specifically, 
the 3-state Markov decision-analytic model developed by Roche is compared to 
partitioned survival and multi-state modelling.  
 The main source of data in this Markov decision-analytic model is the CLL-8 
trial [21]. It compared rituximab in combination with fludarabine and 
cyclophosphamide (RFC) versus fludarabine and cyclophosphamide alone (FC) for 
the first line treatment of chronic lymphocytic leukaemia. The trial had the outcomes 
progression-free survival and overall survival for each patient allowing focus to be on 
the three states progression-free, progression and death (and the transitions 
between them). There were 408 patients in the RFC arm and 409 patients in the FC 
arm. There were 106 progressions, 23 deaths after progression and 21 deaths 
5 
 
without progression amongst those in the RFC arm. In the FC arm there were 148 
progressions, 27 deaths after progression and 26 deaths without progression.  
Patients were in the trial for up to 4 years and not all of them were observed 
to the end of their life. It was estimated that only 1.3% of the cohort would survive 
beyond 15 years [20: p109] and this informed the manufacturer’s decision to use a 
15 year time horizon. We used data from the same trial for the partitioned survival 
and multi-state modelling approaches and used the same time horizon as the 
manufacturer for comparison purposes. 
 
Estimation of mean survival 
 
Estimates of mean survival were obtained by calculating the area under the 
extrapolated survival curves. All areas under survival curves were calculated using 
the trapezoidal rule with increments of 1/12 years, equivalent to the cycle length of a 
month in the manufacturer’s Markov decision-analytic model. However, due to 
computational issues with the Gompertz distribution, the calculation of transition 
probabilities with the multi-state modelling used increments of 1/12 years up to 9 
years followed by increments of 1/144 years up to the 15 year time horizon. This 
shortening of the cycle length after 9 years was needed to overcome a difficulty in 
meeting the requirement that differences in cumulative hazards between consecutive 
time points were below one. After this adjustment to allow calculation of transition 
probabilities, only the probabilities at 1/12 year increments were involved in the 
trapezoidal rule calculations, consistent with other approaches. Our choice of 1/144 
year increments was based on ease of calculation of multiples of 1/12. For each of 
the three approaches, results for mean Life Years and QALYs are presented for 
each treatment arm. All Life Year and QALY calculations were discounted at an 
annual rate of 3.5%, the approach taken by the manufacturers in their Markov 
decision-analytic model. 
 
The next three sections detail each of the approaches in turn. 
 
Partitioned survival 
Partitioned survival involves partitioning overall survival into states of interest. As the 
three states of interest in this illustration were progression-free, progression and 
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death, the required partitioning of overall survival (OS) is achieved using 
progression-free survival (PFS). The two trial outcomes progression-free survival 
and overall survival were each modelled directly using parametric regression to allow 
extrapolation. This approach did not consider post-progression survival directly. 
Instead, the mean time in progression was derived from the difference in the area 
under the two survival outcomes that were considered directly. We considered six 
standard distributions in the modelling for each trial outcome: exponential, Weibull, 
Gompertz, log-logistic, log normal and generalised gamma. The assessment of fit to 
the observed data for each of the predicted probabilities was based on AICs, Cox-
Snell residuals and visual comparison with Kaplan-Meier estimates.  
 
Initially, for the two survival outcomes considered directly, we carried out 
extrapolation by fitting parametric regressions to the whole Kaplan-Meier curve and 
extending the predictions out to 15 years. For progression-free survival, this 
approach produced predictions that adequately represented survival of zero upon 
extrapolation to 15 years. However, this was not the case for overall survival. There 
was a high level of censoring for overall survival. By the end of the trial observation 
period of 4 years, there were still 85% of patients alive. None of the extrapolations 
using any of the distributions produced survival probabilities close to zero by 15 
years, with 50% being the lowest achieved. Therefore, for overall survival, 
extrapolation based on starting from the tail end of the Kaplan-Meier curve was 
undertaken. An approach, outlined by Tappenden et.al [16], was used to fit a linear 
regression to the tail of the Kaplan-Meier curve and then back-transform the 
predictions to the equivalent using a parametric regression. This approach 
accommodated fitting regressions when the starting time point was beyond zero and 
survival had dropped below one, as is the case in the tail of a Kaplan-Meier curve. It 
involved rearranging the survival function of the parametric distribution into a function 
that had a linear, or other simple relationship, with time. For example when an 
exponential fit to the tail data was desired, the exponential survival function S(t)=e- λt 
was rearranged into log(S)= - λt, which meant the linear regression log(S)~ t could 
be performed, with the intercept constrained to be zero. The coefficient for t in this 
linear regression was then used as –λ in the exponential survival function. Similarly, 
a rearrangement of the Weibull survival function S(t)= meant the line log(-log(S)) 
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= a+ b log(t) could be fitted using linear regression, with the coefficients of a and b 
representing log λ and γ respectively. Time t was measured from the start of the tail. 
The regression that was fitted to the tail was then extrapolated to 15 years. Each of 
the treatment groups was considered separately. To decide the eventual “tail end” of 
the Kaplan-Meier curve to use, each of the unique observed times was considered 
as a starting point for the tail. The starting point chosen was the latest time that 
resulted in an extrapolation that reached zero by 15 years. This produced predictions 
that adequately represented a time horizon of 15 years for the FC arm but not the 
RFC arm. Therefore, for the RFC arm, the survival probabilities in the extrapolated 
period were derived by multiplying the logarithm of the extrapolated probabilities in 
the FC arm by the treatment hazard ratio from the observed period, and then taking 
the exponential of the result.  
 
Markov decision-analytic modelling approach adopted by the manufacturer 
 
The 3-state Markov decision-analytic model used by the manufacturer in their 
economic evaluation submitted to NICE is shown in Figure 1. 
 
PUT FIGURE 1 HERE 
 
The three transitions progression-free -> progression, progression-free -> death 
without progression and progression -> death were modelled. The model measured 
time in discrete monthly cycles. The manufacturers took the usual approach in 
Markov decision-analytic modelling of assigning transition probabilities before 
modelling started. The assumptions made by the manufacturer for each of the 
transitions were as follows: 
 
 progression -> death 
A monthly probability of 0.0405 was used, the same for each arm. It was based on 
an assumption of a constant death rate that was derived from the inverse of the 
mean of 24.1791 months from the Kaplan-Meier estimate of post progression 
survival 
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 progression-free -> death 
the observed rate of death whilst progression-free, or an age-specific background 
mortality rate [22], whichever was largest. The observed monthly probability of death 
whilst progression-free was 0.0012 and 0.00139 in the RFC and FC arms 
respectively. 
 
 progression-free->progression 
This was calculated by adding together the probability for progression-free -> death 
and the probability of staying in the progression-free state, and then subtracting the 
result from one. The probability of staying in the progression-free state was based on 
a Weibull regression fitted to the observed progression-free survival data that was 
then extrapolated to 15 years. This was identical to the Weibull regression used for 
progression-free survival in the partitioned survival approach. 
 
The model was built in Excel following a cohort of patients from the initial 
progression-free state over a series of cycles, with movement between states based 
on the transition probabilities already assigned. Extrapolation was performed by 
extending the probabilities to the target time horizon of 15 years. The manufacturer 
used a “clock-reset” approach in that, for the modelling of the progression -> death 
transition, time was set back to zero as patients first entered the progression state. In 
the continuous time state-transition modelling framework, resetting the clock in this 
way is considered a semi-Markov approach. However, the approach used was not 
semi-Markov in the typical sense under the discrete time framework. This was 
because it did not involve tunnel states or the use of multi-dimensional transition 
matrices to incorporate time-dependency and only involved simulation of a single 
cohort.  
   
Multi-state modelling  
The multi-state modelling approach fits the same model as the Markov decision-
analytic modelling above, in that it uses the same three states and transitions 
between them. Unlike with the approach commonly used in Markov decision-analytic 
modelling, this multi-state modelling approach builds survival regression models of 
each of the transitions directly using the individual patient data. It uses the exact time 
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of transitions and therefore is a continuous time state-transition framework, rather 
than the discrete time framework used in Markov decision-analytic modelling. The 
background to the method is explained in a tutorial by Putter et.al [23], on which 
much of the explanation in this section is based.  
 As with Markov decision-analytic modelling, two types of model can be fitted 
with this multi-state modelling approach: Markov and semi-Markov models. Further 
details are available in [23]. With each of these models it is possible to build state-
arrival extended models. The term “state-arrival extended (semi-) Markov“ is 
described in [23] as a model of an  
“ i -> j transition hazard that depends on the time of arrival at state i.”  
It involves including in a model a covariate that represents patients’ history and as 
such provides a useful tool to help decide whether the Markov property holds. The 
effect size and statistical significance of the covariate (which could be time in the 
previous state, or any function thereof) can aid the decision.  
As a preliminary analysis, a Cox state-arrival extended model for progression 
-> death - including a covariate for the time in the previous state - was fitted. This 
was purely for the purpose of aiding the decision of whether to accept the Markov 
assumption. It was a Cox model in the sense that the baseline hazard did not follow 
a specified distribution. It was strictly a Markov, rather than semi-Markov, model 
because time was measured from first entering the initial (progression-free) state. It 
was only this transition that affected the decision of whether the Markov assumption 
was reasonable, as the other transitions did not involve any history as they started in 
the initial state. 
 We found evidence to suggest the Markov property did not hold (not shown) 
and proceeded to use a semi-Markov approach. For each of the transitions, a 
parametric approach to regression was then taken to allow extrapolation of survival. 
In a similar manner to the manufacturer’s Markov decision-analytic model, 
extrapolation was carried out by extending the underlying distribution used for the 
hazard to the target time horizon of 15 years. Standard distributions were considered 
for the modelling of each transition: exponential, Weibull, Gompertz, log-logistic, log 
normal and generalised gamma. AICs are often used to decide between different 
models. However, they only provide information about the fit to the observed data, 
and not on how reasonable the extrapolation looks.  In addition, we did not consider 
AICs, or other similar criteria, because the approach involved modelling transition 
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hazards in a competing risks scenario. When competing risks are involved, there is 
no longer the one-to-one relationship between the hazard and survival probabilities 
there is in the absence of competing risks. That is to say, the hazard of a particular 
event cannot simply be derived from the probability of the survival, because survival 
is based on a combination of two or more hazards rather than just one. With 
competing risks, the term survival is reserved for survival free from any of the events 
(event of interest or competing). The concept of cumulative survival from a particular 
event is not meaningful in a competing risks setting, as it does not recognise that 
competing events can also occur. Instead, the cumulative incidence of a particular 
event is used, as it recognises that other events can occur, through the use of 
survival free from any of the events in its calculation. In addition, the effect of a 
covariate on a hazard of an event can be different from its effect on the cumulative 
incidence of the event, due to the effect of the covariate on the hazard of a 
competing event. More generally, in multi-state models, state occupancy 
probabilities involve combining the hazards for each transition into that state. 
Therefore, comparing AICs of models for hazards of individual transitions does not 
correspond to assessing the state occupancy probabilities that are ultimately of 
interest. AICs can be used in competing risks scenarios when cumulative incidences 
are modelled directly, such as in the Fine and Gray subdistribution hazards model 
[24]. However there is no known equivalent to AIC, or other similar criteria, 
appropriate for this approach. Instead, the resultant model was chosen based on a 
visual assessment of relevant plots that achieved a balance of a good fit to the 
observed data and a reasonable extrapolation to 15 years. 
  
Software used 
All analysis was carried out using R version 3.0.1 [12]. The multi-state 
modelling was undertaken using the mstate package [11]. Adaptations were made 
by the authors to accommodate parametric regression rather than the Cox semi-
parametric approach. The phreg and aftreg functions in the eha package [25] and 
the flexsurvreg function in the flexsurv package [26] were used to fit 
parametric regression models. The phreg function was used to fit exponential, 
Weibull and Gompertz proportional hazards models. Accelerated failure time log-
logistic and log-normal models were fitted using the aftreg function. The 
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flexsurvreg function was used to fit generalised gamma models. The Cox 
cumulative hazards were replaced with parametric equivalents and were used as 
arguments in the mssample function for prediction purposes. 5000 simulations were 
used with the mssample function to sample paths from the multi-state model. The 
mssample function simulates all relevant paths (all possible transition journeys) 
through the multi-state model in order to calculate transition/state occupancy 
probabilities [27]. Areas under the extrapolated survival curves were estimated using 
the trapz function in the caTools package [28]. A tutorial explaining how to 
implement the approach is detailed elsewhere [10]. 
 
RESULTS 
 
Modelling results for each approach 
Tables 1a and b show the results of modelling from the partitioned survival and multi-
state modelling approaches, respectively. For the modelling of progression-free 
survival in the partitioned survival approach, a single Weibull regression was used 
which was extrapolated to 15 years. For the modelling of overall survival in the 
partitioned survival approach, the observed and extrapolated sections were based 
on different models. The observed section was based on a single exponential model. 
A Weibull model was used for the extrapolated section of FC and then the treatment 
hazard ratio in the observed period was applied to the FC probabilities to obtain 
those for RFC. 
 
PUT TABLE 1a AND b HERE 
 
The modelling of progression-free survival (i.e. the composite event outcome 
progression or death without progression) using the partitioned survival approach 
resulted in a hazard ratio (95% CI) of 0.595 (0.473, 0.748), indicating a reduced risk 
for the RFC group. This was very similar to the hazard ratio of 0.572 (0.446, 0.735) 
from the modelling of progression-free -> progression using the multi-state modelling 
approach. This was because the composite event progression or death without 
progression was dominated by progression events. 
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The modelling of overall survival (i.e. the event outcome death with or without 
progression) using partitioned survival over the observed period of the trial had a 
hazard ratio of 0.753 (0.505, 1.123) for RFC vs FC. When this outcome was split into 
the two transitions progression-free -> death without progression and progression -> 
death using multi-state modelling, a change in the direction of the effect was 
apparent for progression -> death. However there was no evidence of a statistically 
significant treatment effect for either of the two transitions involving death in the 
multi-state modelling approach or the modelling of death using the partitioned 
survival approach. 
The Markov decision-analytic modelling assumed no treatment effect for 
progression -> death  ̶ equivalent to a hazard ratio of 1 with no uncertainty  ̶ whereas 
the multi-state modelling resulted in a treatment hazard ratio of 1.408 (0.806, 2.461). 
No other transitions in the Markov decision-analytic modelling could be expressed as 
the equivalent of a hazard ratio because the transitions were not modelled using 
regression. The probabilities of transition were instead based on the manufacturer’s 
assumptions. 
 
Visual assessment of the fits 
 
In this section the fit from each of the modelling approaches was assessed informally 
by inspecting relevant plots. 
Probability of being in progression  
 
The vertical solid lines on Figures 2a and 2b show the times at which there were less 
than 20 patients at risk of death after progression and therefore the proportion 
estimates were less reliable. They therefore provide a dividing line between the 
periods of observation and extrapolation. In addition, the shaded areas show the 
95% confidence intervals for the observed proportions (created using 5000 
bootstrapped samples). 
 
 
PUT FIGURE 2A/B HERE 
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For the RFC arm, all approaches provided a good fit to the observed data up until 
the vertical line (Figure 2a). After this point, there was a marked difference between 
the approaches in where and when the predictions of being in progression peaked. 
The partitioned survival approach and the multi-state modelling were the only 
methods to reach zero by 15 years. 
For the FC arm, the partitioned survival and multi-state modelling approaches 
provided a good fit to the observed data up until the vertical line (Figure 2b). The 
Markov decision-analytic modelling only provided a good fit to the observed data up 
to 2.3 years. Again, there was a marked difference between the approaches in the 
peaks. All three approaches reached zero by 15 years as required. 
 
Progression-free to death without progression 
 
Figure 3 shows, for each treatment arm, the competing risk cumulative incidence 
estimate of progression-free -> death without progression together with the 
predictions from the multi-state modelling. It can be seen that the multi-state 
modelling fitted the observed data moderately well. These predictions were possible 
because the multi-state modelling allowed the state occupancy probabilities of death 
to be split into death without progression and death after progression.  
 
PUT FIGURE 3 AND FIGURE 4 HERE 
 
Progression to death 
 
Figure 4 shows, for each treatment arm, the Kaplan-Meier estimate of  
progression -> death together with the predictions from the multi-state modelling and 
the manufacturer’s assumption. It can be seen that the extrapolation for both 
methods was fairly good at reaching one by 15 years. For RFC, the multi-state 
modelling fitted the Kaplan-Meier estimate quite well, and FC to a lesser extent. 
However the manufacturer’s assumption was less well-fitting to each of the treatment 
arms.  
 
 
Progression-free survival 
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The partitioned survival approach and the Markov decision-analytic modelling were 
based on the same fit to progression-free survival and therefore only one curve is 
shown to represent both approaches (Figure 5). For both treatment arms, each of 
the three approaches appeared to provide a good fit to the Kaplan-Meier estimate. 
The extrapolation using multi-state modelling reached zero somewhat earlier than 
the other approaches. This seems more plausible as it allows those patients who 
reach progression to spend time in that state before reaching the absorbing state 
death. It is compatible with all patients reaching death by 15 years. 
 
PUT FIGURE 5 HERE 
 
Overall survival  
 
Figures 6a and 6b show the Kaplan-Meier estimates of overall survival together with 
the predictions from each of the modelling approaches for the RFC and FC arms, 
respectively. The partitioned survival and multi-state modelling fitted the observed 
data over the first 4 years reasonably well. The Markov decision-analytic modelling 
overestimated survival over the first 2 years. All approaches reached zero by 15 
years for FC. However the multi-state modelling was the only approach to do so for 
RFC.  
 
 
PUT FIGURE 6A/6B HERE 
 
Comparison of mean life years/QALYs 
 
The comparison presented in this article is not a congruous comparison, because 
the approaches did not make all the same assumptions with regards to the transition 
probabilities/hazards. However, as can be seen in Appendix 1, a model built using 
this multi-state modelling approach and one created using the common approach of 
Markov decision-analytic modelling produced very similar results, when they made 
the same assumptions. We now comment on how the different assumptions 
influenced the differences in results between the approaches. 
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Table 2 shows the mean Life Years and QALYs for each of the approaches. Mean 
QALYs were calculated by assuming a utility of 0.8 for the time spent progression-
free and 0.6 for the time spent in progression, the approach used by the 
manufacturer in the Markov decision-analytic model.  
 
PUT TABLE 2 HERE 
 
Table 2 shows that the manufacturer’s Markov decision-analytic modelling resulted 
in larger overall benefits than any of the other approaches. This was primarily due to 
that approach producing smaller decrements whilst in Progression of -0.11 for mean 
Life Years and -0.07 for mean QALYs. This reflected the manufacturer’s assumption 
of no treatment effect for the progression -> death transition. They based this 
decision on the log-rank test for the difference in Kaplan-Meier estimates of post-
progression survival, which did not provide evidence of a statistically significant 
effect of treatment (p-value = 0.395). In contrast, the modelling of the progression -> 
death transition using the multi-state modelling resulted in a hazard ratio of 1.408 for 
treatment. This led to a decrement of -0.49 and -0.29 in mean Life Years and 
QALYs, respectively, whilst in Progression. There were similar corresponding 
decrements whilst in Progression with the partitioned survival approach of -0.53 and 
-0.32.  
 
Another contribution to the differences in overall benefit was the mean Life Years 
and QALYs spent Progression-free. The largest benefit was found with the 
manufacturer’s Markov decision-analytic modelling and the partitioned survival 
approach, which used the same Weibull distribution to model progression-free 
survival. Mean Life Years (QALYs) gained of 1.18 (0.95) were found whilst 
Progression-free. The corresponding results were more modest with the multi-state 
modelling at 0.81 (0.65). 
 
The manufacturer’s Markov decision-analytic model had the largest overall benefit as 
a result of the largest increment whilst Progression-free and the smallest decrement 
whilst in Progression. In contrast, the smallest overall benefit was found with the 
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multi-state modelling due to the combination of the smallest increment whilst 
Progression-free and a relatively large decrement whilst in Progression. 
 
In Appendix 2, the results are shown separately for the observed period of the trial 
and the unobserved extrapolation period. The approaches were generally 
comparable over the observed period. However, in the unobserved extrapolation 
period, more of a discrepancy was apparent. 
 
The mean costs were then incorporated to allow cost-effectiveness to be evaluated 
(Table 3). Details of the assumptions made with regards to mean costs as part of a 
full cost-effectiveness analysis can be found elsewhere [10].  
 
 PUT TABLE 3 HERE 
 
Table 3 shows that the partitioned survival approach and manufacturer’s Markov 
decision-analytic modelling deemed the treatment cost-effective, with Cost per QALY 
gained of £16,308 and £13,189 respectively. However the results were less 
conclusive when the multi-state modelling approach was used with a Cost per QALY 
gained of £29,022, close to the maximum of the range of £20,000 to £30,000 
willingness to pay threshold in the UK.  
 
DISCUSSION 
 
This article has compared survival estimates - of Life Years and QALYs - using the 
multi-state modelling approach and the partitioned survival and Markov decision-
analytic modelling approaches commonly used in cost-effectiveness analysis. Cost-
effectiveness results were also compared between the approaches. The different 
assumptions used for the modelling of the transitions led to different results. In 
particular, the discrepancy in results led to differing ICERs which could affect 
conclusions for cost-effectiveness. We recommend that analysts liaise with clinicians 
and use registry data and/or external sources to help gather evidence to ensure 
assumptions are realistic. In our comparison, for ease of demonstration across 
approaches, we used the same 15-year time horizon as in the manufacturer’s 
existing Markov decision-analytic model. However, when analysts are undertaking 
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their own modelling, we advocate checking that the time horizon and extrapolation to 
that point is realistic in a clinical sense, and to rigorously check all other assumptions 
used in models. In our related analysis where the approaches used the same 
assumptions (Appendix 1) it was apparent that the actual approach used had less of 
an effect on any discrepancy in results than the differing assumptions made within 
each approach. 
Multi-state modelling is an alternative elegant way of estimating transition 
probabilities. This multi-state modelling approach uses the individual patient data 
directly to model the transitions and negates deciding on transition probabilities a 
priori. It uses the exact times of transition and as such does not require modelling 
over (arbitrary) discrete cycles, nor does it require the use of tunnel states. 
Additionally, the multi-state modelling approach demonstrated in this paper can 
incorporate parametric distributions for hazards, which as well as allowing 
extrapolation of survival, can permit hazards that vary over time if required. Given 
the modelling at the individual patient level, multi-state modelling also provides an 
alternative to microsimulation [29]. 
In this illustration we had the individual patient level data (IPD). This meant we 
were able to build a state-arrival extended model to help decide whether the Markov 
assumption was reasonable. We found evidence to suggest a violation of the 
assumption and proceeded to use a semi-Markov approach to relax the assumption. 
When modellers have insufficient power to detect violations of the Markov 
assumption, and have doubts over whether it holds, then a semi-Markov multi-state 
modelling approach would be worth considering. 
When IPD are not available, then a semi-Markov approach can still be used, if 
Kaplan-Meier survival curves related to all relevant transitions are available. 
However, if a Markov and/or state-arrival extended approach is desired without IPD, 
then information on relevant model coefficients will be required from an external 
source. The cumulative hazards necessary for the calculation of transition 
probabilities can be derived from this model output, instead of deriving them from 
direct regression modelling of the data. Functions to perform multi-state modelling 
without IPD are included in our prior tutorial paper [10]. 
The modelling of the progression -> death transition resulted in a hazard ratio 
for treatment of 1.408 with the multi-state modelling. It could be argued that a hazard 
ratio of this magnitude is over-fitting the data, given the size of the sample and the p-
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value associated with the hazard ratio. However, we would argue that this should be 
used as a best estimate of effect for a subsequent economic evaluation, rather than 
just assuming no effect which was likely due to a lack of statistical power, and that 
the uncertainty in model parameters be captured in sensitivity analyses that are 
carried out later in the evaluation. A fuller assessment of the uncertainty in the 
parameters is included in a tutorial-based paper which demonstrates how to do an 
economic evaluation wholly in R, including deterministic and probabilistic sensitivity 
analyses [10]. However, if over-fitting is of concern, shrinkage [30] or a Bayesian 
approach [31] can provide elegant solutions. We also strongly encourage modellers 
to consider modelling uncertainty by calculating bootstrapped confidence intervals 
for the transition probabilities in each model considered. This was outwith the scope 
of this paper and has been “left on the table”. 
To allow comparison with the Markov decision-analytic modelling adopted by 
the manufacturer, this illustration has been limited to a very simple model using 
treatment as the only covariate in the modelling of the three transitions. When IPD is 
available we recommend making full use of the data and considering a multi-state 
modelling approach. Incorporating other covariate information whichever modelling 
approach is adopted would also be worthwhile, provided the number of patients 
experiencing transitions was of sufficient size, and should lead to improved 
predictions of transition probabilities with reduced uncertainty. 
When extrapolation is required for the partitioned survival approach, deciding 
which method to use is not trivial. However the extrapolation of survival can be even 
more complex with a state-transition approach, such as the commonly used Markov 
decision-analytic modelling or this multi-state modelling framework. With the 
partitioned survival approach, there is only one Kaplan-Meier curve at a time to 
consider and extrapolate for each survival outcome. With the modelling of transitions 
the probabilities are not based on one outcome, but transitions which are interlinked. 
The models often include intermediate states with probabilities that need to 
represent that patients can flow in, flow out or remain in that state at any given time. 
When evaluating different parametric distributions, they should be considered for 
each transition simultaneously and this is not necessarily trivial. For example, for this 
illustration six standard distributions were considered for each of the three transitions 
= 63 = 216 combinations for each treatment before deciding on the final model. 
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Consequently, we recommend visually assessing the fits to immediately rule out 
those that do not fit well from any further consideration. 
In the illustration in this paper it was assumed that transition times were 
known exactly for each patient and were continuous, rather than being measured 
discretely over a series of cycles as in the spreadsheets often used in health 
economics. Multi-state modelling using the continuous-time framework is normally 
built with statistical software. This means that there are no spreadsheets that need to 
be set up ready to be populated, and the syntax-based approach means there is a 
written record of what was done contained in just one file. Building the models is a lot 
less computer intensive and there can be considerable time savings. For example, 
obtaining the state occupancy probabilities from a Markov model using this 
framework only requires one line of code that produces output in 1 second. Even the 
simulation involved to produce the state occupancy probabilities from the semi-
Markov model in this illustration only took 90 seconds. It is also possible to 
undertake multi-state modelling when times are not known exactly but are instead 
interval-censored using the R msm package [32], providing another efficient 
alternative to spreadsheets.  
 In each of the approaches presented in this paper, the assumptions used with 
regards to transition probabilities/hazards did not appear at face value to be 
unreasonable. Modellers, due to time constraints, may limit the number of 
approaches they consider to those with which they are most familiar. However, the 
comparison illustrated in this paper has highlighted that different assumptions can 
lead to different conclusions with regards to effectiveness and cost-effectiveness. 
We therefore recommend that any assumptions used are rigorously checked to 
ensure they are realistic. We also advise that the assumptions are subject to 
appropriate sensitivity analyses as part of a full cost-effectiveness analysis.  
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TABLES AND FIGURES 
Table 1a Partitioned survival modelling results 
Partitioned survival 
         distribution coefficient  s.e HR (95%) CI     p-value 
              
 progression-free survival  
(event: progression or death) Weibull 
    
 
treatment: RFC vs FC 
 
-0.519 0.117 0.595 (0.473, 0.748) <0.001
 
log(scale) 
 
1.237 0.060 
  
 
log(shape) 
 
0.310 0.051 
  
       overall survival  
(event: death with or without progression) 
            observed period (0-3.6 years) Exponential 
   
 
treatment: RFC vs FC 
 
-0.284 0.204 0.753 (0.505, 1.123) 0.164 
 
log(scale) 
 
2.753 0.137 
  
       extrapolation (3.6 to 15 years) * 
     
 
Weibull shape 
 
2.257 0.484 
  
 
Weibull log(scale)  -4.377 0.659  
 * derived from a linear regression using the approach described in [16] 
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Table 1b Multi-state modelling results (Gompertz distribution used for each 
transition) 
Multi-state model 
     
         coefficient  s.e HR (95%) CI          p-value 
progression-free -> progression 
    
 
treatment: RFC vs FC 0.542 0.128 0.572 (0.446, 0.735) <0.001 
 
shape 0.474 0.068 
  
 
log(scale) -2.187 0.13 
  
      progression-free -> death without progression 
    
 
treatment: RFC vs FC -0.343 0.294 0.710 (0.399, 1.262) 0.243 
 
shape -0.487 0.207 
 
 
 
log(scale) -2.825 0.265 
  
      progression -> death  
    
      
 
treatment: RFC vs FC 0.342 0.285 1.408 (0.806, 2.461) 0.229
 
shape 0.174 0.244 
 
 
 
log(scale) -1.627 0.267 
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Table 2 Mean Life Years and QALYs 
 
 
 
Partitioned Survival  
Markov decision-analytic 
model Multi-state modelling 
 RFC FC  Incremental RFC FC  Incremental RFC FC  Incremental 
Mean Life Years 5.96 5.31 0.65 5.73 4.65 1.07 5.29 4.97 0.32 
Mean Life Years Progression-free 4.10 2.92 1.18 4.11 2.93 1.18 3.35 2.55 0.81 
Mean Life Years in Progression 1.86 2.39 -0.53 1.62 1.73 -0.11 1.93 2.42 -0.49 
          
Mean QALYs 4.40 3.77 0.63 4.26 3.38 0.88 3.84 3.49 0.35 
Mean QALYs Progression-free 3.28 2.34 0.95 3.29 2.34 0.94 2.68 2.04 0.65 
Mean QALYs in Progression 1.11 1.43 -0.32 0.97 1.04 -0.07 1.16 1.45 -0.29 
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Table 3 Incremental cost-effectiveness ratios 
 
 
Partitioned survival 
 
Markov decision-analytic modelling 
 
Multi-state modelling 
 RFC FC Incremental   RFC FC Incremental 
 
RFC FC Incremental 
Mean Life Years 5.96 5.31 0.65 
 
5.73 4.65 1.07 
 
5.29 4.97 0.32 
Mean QALYs 4.40 3.77 0.63 
 
4.26 3.38 0.88 
 
3.84 3.49 0.35 
Mean Total Cost £25,369 £15,123 £10,246 
 
£25,595 £13,978 £11,617 
 
£25,261 £14,960 £10,301 
Cost per Life Year Gained 
  
£15,694 
   
£10,825 
   
£31,970 
Cost per QALY gained     £16,308     
 
£13,189 
 
  
 
£29,022 
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Figure 1 Markov decision-analytic model diagram 
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Figure 2a and 2b: Time in progression 
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Figure 3 Progression-free to death without progression 
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Figure 4 Progression to death 
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Figure 5 Progression-free survival 
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Figure 6 Overall survival 
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